Outlook Therapeutics FY26 Q3 net loss narrows to $20.32 million; revenue drops to $9,000
OTLK•Management targets U.S. launch of LYTENAVA by end-2026
Management plans a U.S. launch of FDA-approved LYTENAVA by end-2026, targeting potential annual U.S. sales above $500 million by 2030.
Q3 results show narrower loss but sharply lower revenue
Outlook Therapeutics posted a GAAP net loss attributable to common stockholders of $20.3 million, or $0.15 a share, in Q3 FY2026.
Loss per share narrowed from $0.55 a year earlier, reflecting a larger share base.
Revenue fell to $9,000 from $1.51 million a year earlier, while operating loss narrowed to $10.81 million from $15.75 million.
Adjusted net loss attributable to common stockholders (non-GAAP) improved to $10.9 million, or $0.09 a share, from $15.8 million.
